The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

Courtney D. DiNardo, MD, MSCE, discusses the FDA approval of decitabine and cedazuridine plus venetoclax in acute myeloid leukemia.

Treatment with subcutaneous blinatumomab generated high CR rates across 2 dosing regimens in pretreated, relapsed/refractory, Ph-positive B-ALL.

Branko Cuglievan, MD, discusses data for revumenib in the pediatric R/R KMT2AR-acute leukemias subgroup from AUGMENT-101.

Pavlos Msaouel, MD, PhD, discusses the rationale for examining panitumumab-based treatment in SMARCB1-deficient RMC.

Jennifer Marvin-Peek, MD, discusses data for azacitidine, venetoclax, and ivosidenib, in IDH1-mutated acute myeloid leukemia and their significance.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in May 2026.

New spatial atlas of immune cell structures reveals how key features vary across tumor types and influence patient outcomes.

The top 5 OncLive TV videos of the week cover insights in breast cancer, ovarian cancer, prostate cancer, acute myeloid leukemia, and mantle cell lymphoma.

Sharon Giordano will receive the Gianni Bonadonna Breast Cancer Award for significant contributions to breast cancer care and research .

The phase 3 WU-KONG28 data showed that first-line sunvozertinib improved PFS and ORR vs chemotherapy in EGFR exon 20–mutant NSCLC.

Neil D. Gross, MD, FACS, discusses how anti–PD-1 therapy is changing treatment approaches in advanced CSCC.

The University of Texas MD Anderson Cancer Center announced that Albert Koong, MD, PhD, has been appointed chief scientific officer.

The top 5 OncLive TV videos of the week cover insights in breast cancer, ovarian cancer, prostate cancer, acute myeloid leukemia, and mantle cell lymphoma.

Neil D. Gross, MD, FACS, discusses the heterogeneous nature of advanced CSCC.

Researchers found that macrophages are associated with response to chemotherapy before treatment in triple-negative breast cancer.

Sanam Loghavi, MD, discusses the specific updates to the WHO diagnostic criteria in acute myeloid leukemia.

The FDA has issued a ‘safe to proceed’ for an application for a novel CAR T-cell therapy in CD94-positive lymphomas.

The top 5 OncLive TV videos of the week cover insights in breast cancer, acute myeloid leukemia, bladder cancer, multiple myeloma, and melanoma.

Sanam Loghavi, MD, discusses updated WHO diagnostic criteria for acute myeloid leukemia and its significance for diagnoses and treatment selection.

Courtney D. DiNardo, MD, MSCE, discusses the FDA approval of decitabine/cedazuridine plus venetoclax in acute myeloid leukemia.

Luhua (Michael) Wang, MD, discusses the implications of the FDA approval of brexu-cel for the treatment of adult patients with relapsed/refractory MCL.

Luhua (Michael) Wang, MD, discusses the FDA approval of brexu-cel in mantle cell lymphoma and what to know about CAR T-cell therapy in clinical practice.

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.

Theresa A. Guise, MD, FASBMR, and Stephanie S. Watowich, PhD, discuss their elections as AAAS fellows and offer guidance for early-career investigators.

Shubham Pant, MD, MBBS, explains the unique "on-state" binding mechanism of daraxonrasib.

Shubham Pant, MD, MBBS, discusses the management of dermatologic and GI toxicities associated with the RAS(ON) inhibitor daraxonrasib.

Here is your cheat sheet to all oncology therapeutic options that were cleared or rejected by the FDA in April 2026.

Neil D. Gross, MD, FACS, discusses the importance of year-round vigilance when it comes to skin cancer prevention and education.

Shubham Pant, MD, MBBS, discusses results from the landmark phase 3 RASolute 302 trial for daraxonrasib in previously treated metastatic PDAC.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, endometrial cancer, salivary gland cancer, myeloproliferative neoplasms, and renal cell carcinoma.